AIP
NBIX icon

ARS Investment Partners’s Neurocrine Biosciences NBIX Stock Holding History

ARS Investment Partners’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-4,500
Closed -$373K – 145
2018
Q1 		$373K Hold
4,500
– – 0.05% 130
2017
Q4 		$349K Hold
4,500
– – 0.04% 139
2017
Q3 		$276K Hold
4,500
– – 0.04% 141
2017
Q2 		$207K Buy
+4,500
New +$218K 0.03% 143

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

ARS Investment Partners's NBIX Position: Q2 2018 in Review

ARS Investment Partners sold out of Neurocrine Biosciences (NBIX) in Q2 2018, closing a stake of 4,500 shares — an estimated $373K sold.

ARS Investment Partners first reported a position in NBIX in Q2 2017 and held it in 4 quarters. The position peaked at $373K in Q1 2018. 274 funds tracked by Wall St. Rank hold NBIX as of Q2 2018.

  • ARS Investment Partners reported no remaining Neurocrine Biosciences position as of Q2 2018 after selling out during the quarter.
  • ARS Investment Partners sold 4,500 Neurocrine Biosciences shares in Q2 2018, an estimated $373K.
  • ARS Investment Partners first reported a position in Neurocrine Biosciences in Q2 2017 and held it in 4 quarters.
  • ARS Investment Partners's Neurocrine Biosciences position peaked at $373K in Q1 2018.
  • 274 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2018.

Based on ARS Investment Partners's 13F filing for Q2 2018, filed 13 Aug 2018.